Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Journal of Neurology

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1468-1331.2008.02318.xPMID 19049556
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones.

  2007cited by this paper
• Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.

  2007cited by this paper
• Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.

  2007cited by this paper
• Coenzyme Q10 and exercise training in chronic heart failure.

  2006cited by this paper
• International cooperative ataxia rating scale (ICARS): Appropriate for studies of Friedreich's ataxia?

  2005cited by this paper
• Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

  2005cited by this paper
• Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.

  2004cited by this paper
• Role of Oxidative Damage in Friedreich's Ataxia

  2004cited by this paper
• Frataxin Acts as an Iron Chaperone Protein to Modulate Mitochondrial Aconitase Activity

  2004cited by this paper
• Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial

  2004cited by this paper
• Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial

  2003cited by this paper
• Idebenone treatment in Friedreich’s ataxia

  2003cited by this paper
• A non-essential function for yeast frataxin in iron-sulfur cluster assembly.

  2002cited by this paper
• Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia.

  2002cited by this paper
• Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia

  2002cited by this paper
• Friedreich's ataxia.

  2002cited by this paper
• Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia

  2001cited by this paper
• Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study.

  2001cited by this paper
• Familial cerebellar ataxia with muscle coenzyme Q10 deficiency

  2001cited by this paper
• Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia.

  2000cited by this paper
• Oxidative stress in patients with Friedreich ataxia

  2000cited by this paper
• Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study.

  1999cited by this paper
• Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia.

  1999cited by this paper
• International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology.

  1997cited by this paper
• Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia

  1997cited by this paper
• Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes.

  1997cited by this paper
• Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features.

  1981cited by this paper
• Friedreich's ataxia

  year unknowncited by this paper

• Dietary approaches to Friedreich’s Ataxia: a review

  2025cites this paper
• Blood–Brain Barrier and Neuronal Model Systems for Studying CoQ10 Metabolism

  2025cites this paper
• Oxidative Stress and Antioxidant Therapies in Friedreich’s Ataxia

  2025influential citation
• Friedreich Ataxia and Related Diabetes: Therapeutic Approach Targeting Mitochondrial Dysfunction

  2025cites this paper
• Potent antioxidant and mitochondrial-protective effects of ATH434, a moderate affinity iron chaperone

  2025cites this paper
• Insights into targeted ferroptosis in mechanisms, biology, and role of Alzheimer's disease: an update

  2025cites this paper
• Clinical and cognitive assessment in Friedreich ataxia clinical trials: a review

  2025cites this paper
• Recent Advances in the Treatment Strategies of Friedreich's Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms.

  2024cites this paper
• Present Insights into the progress in gene therapy delivery systems for central nervous system diseases.

  2024cites this paper
• Emerging antioxidant therapies in Friedreich’s ataxia

  2024cites this paper
• Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases

  2023cites this paper
• Apparent Opportunities and Hidden Pitfalls: The Conflicting Results of Restoring NRF2-Regulated Redox Metabolism in Friedreich’s Ataxia Pre-Clinical Models and Clinical Trials

  2023influential citation
• Therapeutic Biomarkers in Friedreich’s Ataxia: a Systematic Review and Meta-analysis

  2023cites this paper
• Follow‐up of 25 patients with treatable ataxia: A comprehensive case series study

  2022cites this paper
• Toward the in vitro understanding of iPSC nucleoskeletal and cytoskeletal biology, and their relevance for organoid development

  2022cites this paper
• Current and emerging treatment modalities for spinocerebellar ataxias

  2022cites this paper
• Depletion and Supplementation of Coenzyme Q10 in Secondary Deficiency Disorders.

  2022cites this paper
• Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review

  2022cites this paper
• Treatment and Management of Autosomal Recessive Cerebellar Ataxias: Current Advances and Future Perspectives.

  2022cites this paper
• Effects of aluminum chloride and coenzyme Q10 on the molecular structure of lipids and the morphology of the brain hippocampus cells

  2021cites this paper
• Novel Therapeutic Challenges in Cerebellar Diseases

  2021cites this paper
• Autosomal Recessive Cerebellar Ataxias

  2021cites this paper
• Coenzyme Q10 effects in neurological diseases.

  2021cites this paper
• The Roles of Coenzyme Q in Disease: Direct and Indirect Involvement in Cellular Functions

  2021cites this paper
• Coenzyme Q10 deficiency in patients with hereditary hemochromatosis.

  2021cites this paper
• Future Prospects of Gene Therapy for Friedreich’s Ataxia

  2021cites this paper
• Clinical Scales of Cerebellar Ataxias

  2021cites this paper
• The Involvement of Anti-Oxidative Response and Mitochondrial Dynamics in the Pathogenesis of Friedreich’s Ataxia: Relevance to the Development of Future Therapeutics

  2020cites this paper
• An open-label pilot study of recombinant granulocyte-colony stimulating factor in Friedreich’s ataxia

  2020cites this paper
• The NRF2 Signaling Network Defines Clinical Biomarkers and Therapeutic Opportunity in Friedreich’s Ataxia

  2020cites this paper
• Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain

  2020cites this paper
• Emerging therapies in Friedreich’s Ataxia

  2020cites this paper
• Coenzyme Q10

  2020cites this paper
• Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies.

  2020cites this paper
• Antioxidant Therapies and Oxidative Stress in Friedreich’s Ataxia: The Right Path or Just a Diversion?

  2020cites this paper
• Disarrangement of Endoplasmic reticulum-mitochondria communication impairs Ca2+ homeostasis in FRDA

  2020cites this paper
• Miniaturized imprinted solid phase extraction to the selective analysis of Coenzyme Q10 in urine.

  2019cites this paper
• The impact of micelle size and increased absorption of ubiquinone using a novel delivery system (AquaCelle®)

  2019cites this paper
• Friedreich ataxia- pathogenesis and implications for therapies.

  2019cites this paper
• Cholestasis: The Close Relationship between Bile Acids and Coenzyme Q10

  2019cites this paper
• Mitochondrial Dysfunction in Friedreich Ataxia Mitochondrial Dysfunction in Friedreich Ataxia

  2019cites this paper
• Recent Advances in the Treatment of Cerebellar Disorders

  2019cites this paper
• Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.

  2019cites this paper
• Molecular diagnosis of coenzyme Q10 deficiency: an update

  2018cites this paper
• Progress in the treatment of Friedreich ataxia.

  2018cites this paper
• Anti-Oxidant Drugs: Novelties and Clinical Implications in Cerebellar Ataxias

  2018cites this paper
• Scales for the clinical evaluation of cerebellar disorders.

  2018cites this paper
• Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich’s Ataxia Models

  2018cites this paper
• Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.

  2018cites this paper
• Emerging therapeutics for the treatment of Friedreich’s ataxia

  2018cites this paper
• Ataxia and coenzyme Q10: an overview

  2018cites this paper
• The Value of Coenzyme Q10 Determination in Mitochondrial Patients

  2017cites this paper
• Relative bioavailability of coenzyme Q10 formulation for paediatric individualized therapy

  2017cites this paper
• Cellular factories for coenzyme Q10 production

  2017cites this paper
• Ataxias: Pathogenesis, Types, Causes and Treatment

  2017cites this paper
• xidative Stress in Fibromyalgia: Pathophysiology and linical Implications

  2017cites this paper
• In Vitro Antioxidant Activity of Idebenone Derivative-Loaded Solid Lipid Nanoparticles

  2017cites this paper
• Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38

  2017cites this paper
• Friedreich Ataxia: current status and future prospects

  2017cites this paper
• 91 – The Cerebellum and the Hereditary Ataxias

  2017cites this paper
• Advances in management of movement disorders in children.

  2016cites this paper
• Management of the ataxias : towards best clinical practice

  2016cites this paper
• Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia?

  2016influential citation
• Emerging therapies in Friedreich's ataxia.

  2016cites this paper
• Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome.

  2016cites this paper
• Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.

  2016cites this paper
• Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia.

  2016cites this paper
• Secondary coenzyme Q10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders.

  2016cites this paper
• The effect of coenzyme Q10 on venous ischemia reperfusion injury.

  2016cites this paper
• Pharmacological treatments for Friedreich ataxia.

  2016cites this paper
• Coenzyme Q10 analytical determination in biological matrices and pharmaceuticals.

  2016cites this paper
• Ataxia Scales for the Clinical Evaluation

  2016cites this paper
• Vitamin Q10 : Property, Production and Application

  2016cites this paper
• Chapter 13 – Friedreich Ataxia

  2016cites this paper
• Quantifiable evaluation of cerebellar signs in children

  2015cites this paper
• Milestones in Friedreich ataxia: more than a century and still learning

  2015cites this paper
• Title Efficient attenuation of Friedreich ' s ataxia ( FRDA ) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell ( hiPSC ) as a drug screening platform

  2015cites this paper
• Antioxidants for the Prevention and Treatment of Multiple Sclerosis

  2015cites this paper
• Prospects of gene and cell therapy for managing cardiac complications in Friedreich ataxia

  2015cites this paper
• Editorial Oxidative Stress in Fibromyalgia : Pathophysiology and Clinical

  2015cites this paper
• Tratamiento de la disfunción mitocondrial con coenzima Q10

  2015cites this paper
• Coenzyme Q 10 Therapy

  2015cites this paper
• New analytical strategies applied to the determination of Coenzyme Q10 in biological matrix.

  2015cites this paper
• Vitamin E and neurodegeneration.

  2015cites this paper
• Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathological alterations in BMCs in a fibromyalgia patient

  2015cites this paper
• Ubiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial

  2015cites this paper
• Oxidative stress in inherited mitochondrial diseases.

  2015cites this paper
• 6 – Hereditäre Bewegungsstörungen

  2014cites this paper
• Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia – open‐label trial

  2014cites this paper
• Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials

  2014cites this paper
• Oxidative Stress and Mitochondrial Dysfunction across Broad-Ranging Pathologies: Toward Mitochondria-Targeted Clinical Strategies

  2014cites this paper
• Targeting mitochondria for neuroprotection in Parkinson disease.

  2014cites this paper
• Therapeutic approaches for the treatment of Friedreich’s ataxia

  2014cites this paper
• Coenzyme Q10 Therapy

  2014cites this paper
• Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.

  2014cites this paper
• Coenzyme Q10 Administration in Community-Acquired Pneumonia in the Elderly

  2014cites this paper
• IGF-1 in Friedreich’s Ataxia – proof-of-concept trial

  2014cites this paper
• Consensus clinical management guidelines for Friedreich ataxia

  2014cites this paper
• Clinical applications of coenzyme Q10.

  2014cites this paper
• A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

  2014cites this paper